In the latest state effort to peel back the curtain on drug pricing, Nevada has adopted a law that requires pharmaceutical companies to disclose prices and costs associated with their asthma medicines, a step that mirrors action taken two years ago on diabetes treatments.
Specifically, drug makers must submit reports to the state detailing costs for producing or acquiring medicines used to treat asthma, as well as profit margins, any financial assistance provided to patients, and the factors contributing to recent, significant price increases.
As with its previous move to require data for diabetes drugs, as well as similar efforts in other states such as California that target all medicines, Nevada lawmakers hope to glean enough information in order to force the pharmaceutical industry to justify price hikes.
About the Author Reprints
